Therapeutic implications for NMDA receptors in mood disorders

Expert Review of Neurotherapeutics

Volumn 13, Issue 7, 2013, Pages 735-737

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

D cycloserine; Glutamate; Glycine transporter inhibitor; GLYX 13; Ketamine; NMDA receptor; Rapid antidepressant

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; AMG 747; AZD 6765; BIOLOGICAL MARKER; BITOPERTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLOSERINE; GLYX 13; KETAMINE; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NRX 1074; PLACEBO; RAPAMYCIN; SARCOSINE; TRAXOPRODIL; UNCLASSIFIED DRUG;

ALLELE; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; MULTICENTER STUDY (TOPIC); NEUROTRANSMISSION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; PYRAMIDAL NERVE CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT RESISTANT DEPRESSION;

HUMANS; MOOD DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84883172245     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.811894     Document Type: Editorial

References (20)

1. Frye MA. Clinical practice. Bipolar disorder - a focus on depression. N. Engl. J. Med. 364(1), 51-59 (2011).
2. Hashimoto K, a A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62(11), 1310-1316 (2007).
3. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 61(2), 105-123 (2009).
4. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. doi:10.1007/s00406-013-0399-y (2013) (Epub ahead of print).
5. Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63(8), 856-864 (2006).
6. Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67(8), 793-802 (2010).
7. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol. Psychiatry 72(7), 537-547 (2012).
8. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 338(6103), 68-72 (2012).
9. Li N, Lee B, Liu RJ et al. mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994), 959-964 (2010).
10. Autry AE, Adachi M, Nosyreva E et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354), 91-95 (2011).
11. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71(11), 996-1005 (2012).
12. Hashimoto K. A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin. Psychopharmacol. Neurosci. 10(1), 59-60 (2012).
13. Ma XC, Dang YH, Jia M et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS ONE 8(2), e56053 (2013).
14. Zarate CA Jr, Mathews D, Ibrahim L et al. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol. Psychiatry doi:10.1016/j.biopsych.2012.10.019 (2012) (Epub ahead of print).
15. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatmentrefractory major depressive disorder. J. Clin. Psychopharmacol. 28(6), 631-637 (2008).
16. Ibrahim L, Diaz Granados N, Jolkovsky L et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 32(4), 551-557 (2012).
17. Heresco-Levy U, Gelfin G, Bloch B et al. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 16(3), 501-506 (2013).
18. Burgdorf J, Zhang XL, Nicholson KL et al. GLYX-13, a NMDA receptor glycinesite functional partial agonist, induces antidepressant-like effects without ketaminelike side effects. Neuropsychopharmacology 38(5), 729-742 (2013).
19. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 17(2), 112-120 (2011).
20. Huang CC, Wei IH, Huang CL et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry doi:10.1016/j. biopsych.2013.02.020 (2013) (Epub ahead of print).